Early-phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease.

ABSTRACT:

Introduction

Recent work suggests that amyloid beta (Aβ) positron emission tomography (PET) tracer uptake shortly after injection ("early phase") reflects brain metabolism and perfusion. We assessed this modality in a predominantly amyloid-negative neurodegenerative condition, Parkinson's disease (PD), and hypothesized that early-phase ¹⁸F-florbetaben (eFBB) uptake would reproduce characteristic hypometabolism and hypoperfusion patterns associated with cognitive decline in PD.

Methods

One hundred fifteen PD patients across the spectrum of cognitive impairment underwent dual-phase Aβ PET, structural and arterial spin labeling (ASL) magnetic resonance imaging (MRI), and neuropsychological assessments. Multiple linear regression models compared eFBB uptake to cogniti

SUBMITTER: Aye WWT 

PROVIDER: S-EPMC11193095 | biostudies-literature | 2024 Apr-Jun

REPOSITORIES: biostudies-literature